Pharmafile Logo
Pharmafocus logo
Advanced Search

FDA approves Novartis’ Afinitor

November 1, 2010
Sales and Marketing Afinitor, Novartis, subependymal giant cell astrocytomas, tuberous sclerosis

Novartis’ drug Afinitor has been approved by US authorities as a first line treatment for patients with benign brain tumours …

News

TranslateMedia ranked 4th in UK Deloitte Technology Fast 50 for 2010

November 1, 2010
Business Services

 TranslateMedia announced today that it has been ranked 4th in this year’s UK Deloitte Technology Fast 50. The Technology Fast …

News
Press release

Pfizer to seek US approval for crizotinib next year

November 1, 2010
Research and Development, Sales and Marketing FDA submission, NSCLC, Pfizer, crizotinib, lung cancer, non-small cell lung cancer

Pfizer will submit its lung cancer candidate crizotinib to the FDA for US approval in the first half of next …

News

German rebates to cost pharma 1 billion euro

November 1, 2010
Sales and Marketing BPI, German pharma market, Germany, Gesetzliche Krankenversicherung, healthcare costs

The pharma industry will contribute over 1 billion euro ($1.4 billion) to Germany’s cost-containment efforts by the end of 2010. …

News

GSK signs rare diseases deal with Amicus

November 1, 2010
Research and Development, Sales and Marketing Amicus Therapeutics, Fabrazyme, Fabry disease, GSK, GlaxoSmithKline, pharmacological chaperones

GlaxoSmithKline is partnering with US biopharmaceutical company Amicus Therapeutics to develop and commercialise its late-stage Fabry disease drug Amigal. GSK …

News

Cross-functional marketing leadership

November 1, 2010
Sales and Marketing Nikki Atkins, WG Consulting Healthcare, leadership, marketing strategies, pharma marketing

Building a multi-disciplinary team across a pharma company is a tough challenge – but the demands of the modern development …

Feature
AstraZeneca

Patent expiries bite into AstraZeneca revenues

October 29, 2010
Sales and Marketing AstraZeneca, Crestor, Q3, Seroquel

Generic competition and a major drop off in pandemic influenza products saw AstraZeneca’s revenue fall for the third quarter. Revenue …

News

MabThera gains maintenance therapy licence

October 29, 2010
Medical Communications, Sales and Marketing MabThera, Rituxan, Roche, lymphoma

Roche’s MabThera has been approved as a maintenance therapy for follicular lymphoma, a common type of blood cancer. Maintenance treatment …

News

Watson submits Crestor copycat

October 28, 2010
Sales and Marketing AstraZeneca, Crestor, Watson, generic, patent

 Watson Pharmaceuticals is seeking to launch a generic version of  AstraZeneca cholesterol blockbuster Crestor, exploiting weaknesses in its patent. The …

News

Rep’s shotgun request misfires

October 28, 2010
Sales and Marketing ABPI Code of Practice, PMCPCA, Sanofi-Aventis

Sanofi-Aventis has been found in breach of the ABPI Code over the conduct of one of its representatives in relation …

News
GlaxoSmitKline's headquarters

GSK makes record whistleblower payout

October 28, 2010
Manufacturing and Production Cheryl Eckard, FDA, GSK, GlaxoSmithKline, manufacturing compliance, whistle blower

GlaxoSmithKline has officially agreed to plead guilty to distributing adulterated drugs made at its now-closed facility in Cidra, Puerto Rico, …

News

Engaging the digital audience

October 28, 2010
Medical Communications Andy Bell, Huntsworth Health, Jon Clark, Talking Point, digital marketing, digital pharma

We live in exciting times. With the rise of social media, people are changing the way they consume information. As …

Feature

NICE refuses cancer drugs Arzerra, Torisel and Levact

October 27, 2010
Sales and Marketing Arzerra, GSK, NICE, Napp Pharmaceuticals, Pfizer, Torisel, Treanda, cancer drugs

NICE has refused to recommend a trio of cancer drugs for NHS use – but in two cases says this …

News

Intercell appoints Staph Leavenworth Bakali

October 27, 2010
Research and Development Intercell, Staph Leavenworth Bakali, appointment, research and development

Austrian biotech company Intercell has appointed Staph Leavenworth Bakali as chief business officer. He will have key responsibilities for the …

Appointment

£600m confirmed for three year Cancer Drugs Fund

October 27, 2010
Sales and Marketing Cancer, Cancer Drugs Fund, NHS, NICE, cancer drugs, value-based pricing

The NHS will get the extra money it was promised to improve patient access to cancer medicines not backed by …

News

Contract research news in brief

October 27, 2010
Research and Development Almac, Kinaxo, MediData Solutions, Quintiles, Ricerca Biosciences, Southern Research Institute, Venn Life Sciences, biofocus, contract research

Our latest crop of contract research news includes updates from Quintiles, Venn Life Sciences, Medidata Solutions, Southern Research Institute, Ricerca …

News

Health outcomes – does anything else matter?

October 27, 2010
Research and Development Les Rose, evidence-based medicine, healthcare outcomes, randomised controlled trials

So the mould of British politics has been broken, and we now have a government with probably a broader range …

Feature

Pharma engages HTA bodies in early-stage drug discussions

October 27, 2010
Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, EMA, European Medicines Agency, GlaxoSmithKline, Johnson & Johnson, health technology assessment, hta

Three pharma companies are taking part in a new pilot to harmonise European standards in health technology assessment (HTA). AstraZeneca, …

News
Blog footer

Digital Pharma: UK’s online dementia mentors

October 26, 2010
Medical Communications Alzheimer's disease, Comprehensive Spending Review, Digital Pharma blog, dementia, patient education

The Department of Health is looking for hundreds of people to become online dementia mentors as part of it ongoing …

News

Sanofi moves teriflunomide into phase III MS trials

October 26, 2010
Research and Development MS, Sanofi, Sanofi-Aventis, TERACLES, multiple sclerosis, relapsing multiple sclerosis, teriflunomide

Sanofi-Aventis is to begin the first phase III study of an oral drug as an add-on to standard therapy in …

News
The Gateway to Local Adoption Series

Latest content

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026

Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development US

January 29, 2026

Five Facts about spinal muscular atrophy

January 28, 2026